SHERIDAN, WYOMING -- June 15, 2026 -- The U.S. Food and Drug Administration has accepted Roche's supplemental Biologics License Application for Tecentriq and Tecentriq Hybreza in combination with chemotherapy as an adjuvant treatment for stage III dMMR/MSI-H colon cancer following surgery. The FDA has granted Priority Review and is expected to issue a decision by October 9, 2026. The filing is supported by Phase III ATOMIC study data showing a 50% reduction in the risk of disease recurrence or death compared to chemotherapy alone, results published in The New England Journal of Medicine.
ATOMIC Trial Data Drives the Regulatory Filing
The ATOMIC study forms the basis of Roche's application. The Phase III, randomised, open-label, multicentre trial enrolled 712 patients with stage III dMMR colon cancer. Participants received either FOLFOX6 chemotherapy plus Tecentriq for twelve cycles followed by Tecentriq monotherapy for thirteen cycles, or FOLFOX6 alone for twelve cycles. The primary endpoint was disease-free survival.
At thirty-six months, disease-free survival reached 86% in the Tecentriq plus FOLFOX6 group versus 76% in the chemotherapy-only group. The safety profile was consistent with prior Tecentriq and FOLFOX6 studies. ATOMIC was sponsored by the National Cancer Institute and conducted by the Alliance for Clinical Trials in Oncology, in partnership with Roche and the Arbeitsgemeinschaft Internistische Onkologie group in Germany.
dMMR/MSI-H Tumour Biology Creates a Defined Patient Population
Approximately 15% of colon cancer patients present with dMMR or MSI-H tumours. These tumour types are characterised by high mutation rates, which create a biological basis for response to immunotherapy. The Tecentriq application targets this specific subgroup of stage III patients — those whose tumours carry the dMMR or MSI-H marker as determined by an immunohistochemistry test such as the VENTANA MMR RxDx Panel.
That biomarker-defined approach is central to how Roche frames the potential clinical impact. Identifying patients whose tumour biology makes them candidates for immunotherapy allows treatment to be tailored from the point of diagnosis, rather than applying a uniform post-surgical regimen to all stage III patients.
Recurrence Risk Defines the Unmet Need in Adjuvant Colon Cancer
Nearly one in three patients with stage III colon cancer relapse within five years of surgery and chemotherapy. Over one million people are diagnosed with colon cancer globally each year. Despite existing surgical and chemotherapy options, that thirty percent recurrence rate within five years has persisted as a clinical problem without an approved immunotherapy-based adjuvant option for this population.
Michael Sapienza, CEO of the Colorectal Cancer Alliance, addressed the significance of the FDA filing: "One in three patients with stage III colon cancer will relapse within five years, underscoring the need for new adjuvant treatment options. This milestone represents a critical step toward a reality where treatment is tailored to a patient's specific tumor biology from the very beginning, giving them a better chance of preventing a recurrence."
Roche Positions Tecentriq as Potential New Standard of Care
Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development, described the filing's clinical implications: "This filing acceptance brings us closer to establishing adjuvant Tecentriq plus chemotherapy as a new standard of care for certain types of early colon cancer. The ATOMIC results demonstrate that Tecentriq plus chemotherapy can substantially reduce the risk of disease recurrence or death, helping more patients remain cancer-free following surgery."
If approved, Tecentriq combined with chemotherapy would represent the first immunotherapy-based adjuvant treatment option for stage III dMMR/MSI-H colon cancer. The potential designation as a new standard of care carries significant implications for oncology practice, treatment protocol design, and the patient population currently managed on chemotherapy alone after surgery.
European Filing and Global Rollout Plans Already Underway
Roche is pursuing parallel regulatory filings beyond the U.S. submission. The company has indicated it is filing with the European Medicines Agency to seek approval for Tecentriq in the adjuvant dMMR/MSI-H colon cancer setting across European markets. That dual-track regulatory strategy reflects the global patient population at stake and Roche's stated aim of bringing an immunotherapy-based option to this group worldwide.
Tecentriq is a monoclonal antibody designed to bind with PD-L1, blocking its interactions with both PD-1 and B7.1 receptors. It is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations, with Tecentriq Hybreza representing the subcutaneous option included in the current sBLA.
For more information on Roche's cancer immunotherapy programme and Tecentriq, visit Roche.